NCT07294924 (PREDICT-ACC) is a clinical trial of fNIRS measurement in Major Depressive Disorder (MDD), sponsored by Kernel.

Who is sponsoring NCT07294924?

NCT07294924 is sponsored by Kernel.

What drugs are being tested in NCT07294924?

Interventions in NCT07294924: fNIRS measurement.

What condition does NCT07294924 study?

NCT07294924 studies Major Depressive Disorder (MDD), fNIRS.

Is NCT07294924 still recruiting?

NCT07294924 is currently recruiting now. Last updated 19 December 2025.

Last reviewed 2025-12-19 · How we verify

NCT07294924: PREDICT-ACC

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Prediction of REsponse to Depression Interventions (Accelerated rTMS) Using Clinical and TD-fNIRS Measurements

Recruiting now Last updated 19 December 2025

What this trial tests

trial testing fNIRS measurement in Major Depressive Disorder (MDD) in 100 participants. Currently enrolling.

Timeline

15 December 2025

Primary endpoint
15 December 2026

15 December 2026

Quick facts

Lead sponsor	Kernel
Status	Recruiting now
Study type	OBSERVATIONAL
Enrollment	100
Start date	15 December 2025
Primary completion	15 December 2026
Estimated completion	15 December 2026
Sites	2 locations across United States

Drugs / interventions tested

fNIRS measurement

Conditions studied

Major Depressive Disorder (MDD) — all drugs for Major Depressive Disorder (MDD) →
fNIRS — all drugs for fNIRS →

Sponsor

Kernel

Who can join

Adults 18 to 75, any sex, with Major Depressive Disorder (MDD) or fNIRS. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This observational, longitudinal, multi-cohort study aims to evaluate functional brain activity in adults undergoing treatment for Major Depressive Disorder (MDD) at participating clinical sites. A separate cohort of healthy adults will be enrolled as a control group. All data collected in this study are for research purposes only and will not influence clinical decision-making or treatment plans. This study will use TD-fNIRS to measure hemodynamic brain responses at rest and/or during tasks in patients receiving accelerated transcranial magnetic stimulation (TMS). Imaging will occur at multiple timepoints (pre-treatment, post-treatment, and follow-ups). Healthy control participants will complete similar measurements at one visit, with the option for a follow-up visit. The primary objectives are to assess feasibility, characterize brain activity patterns, and explore potential biomarkers associated with treatment response.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of fNIRS measurement

Trials testing the same drug.

NCT05996575 — Investigating Mild Cognitive Impairment in Patients And Controls With TD-fNIRS · completed
NCT05427578 — Brain Markers of Depression Vulnerability: the Case of Prefrontal Haemodynamic Response · completed

Other recruiting trials for Major Depressive Disorder (MDD)

Currently open trials in the same condition.

NCT07396272 — A Clinical Trial of Add-on Oral Slow-release Ketamine Treatment in Major Depression · Phase 2 · recruiting
NCT07226661 — Double-blind, Placebo-controlled Study in Adults With Major Depressive Disorder · Phase 2 · recruiting
NCT07324070 — Electroconvulsive Therapy Augmented With Transcranial Magnetic Stimulation for Treatment Resistant Depression · NA · recruiting
NCT06972368 — Home-Based tDCS for Depression in BPD · NA · recruiting
NCT06773949 — Feasibility Trial of Exercise as a Priming Strategy for rTMS Treatment in Difficult-to-Treat Depression · NA · recruiting

Other Kernel trials

Trials by the same sponsor.

NCT05996575 — Investigating Mild Cognitive Impairment in Patients And Controls With TD-fNIRS · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07294924 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Kernel
Last refreshed: 19 December 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07294924.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing